Daily ReportOct 31, 2026
Sepsis, October 31 edition
We read 36 papers and selected 3.
Summary
Today’s strongest sepsis papers addressed both immediate clinical management and emerging mechanism-based therapy. A meta-analysis of 11 randomized trials supported corticosteroids for modest mortality reduction and faster shock reversal, while a nanotherapeutic study identified metabolic restoration of immune cells as a potential strategy for sepsis-induced immunoparalysis. A systematic review also demonstrated major inconsistency in the definition and imaging assessment of septic cardiomyopathy.
Research Themes
- Adjunctive corticosteroid therapy in septic shock
- Metabolic nanotherapy for sepsis-induced immunoparalysis
- Definition and imaging assessment of septic cardiomyopathy
Selected Articles
1. Poly-β-Hydroxybutyrate Nanoparticles Improve Septic Immunoparalysis and Prognosis by Energy-Refreshing via Controlled Release of β-Hydroxybutyrate.
This mechanistic study developed biodegradable poly-β-hydroxybutyrate nanoparticles that provide sustained β-hydroxybutyrate delivery. In vitro, murine in vivo, and ex vivo human monocyte experiments indicated restoration of cellular bioenergetics through the tricarboxylic acid cycle-oxidative phosphorylation axis, with improved survival and immune responsiveness in septic mice.
Impact: The study offers a novel mechanism-based therapeutic concept for sepsis-induced immunoparalysis, a major unmet clinical need. It links controlled metabolic delivery to immune restoration and validates the concept across animal, cellular, and limited human ex vivo systems.
Clinical Implications: The findings are not ready for clinical use but support further development of metabolism-targeted immunotherapy for selected patients with persistent sepsis-associated immunoparalysis. Translation will require pharmacokinetic, toxicology, dosing, and efficacy studies in clinically relevant models.
Key Findings
- The optimized nanoparticles showed spherical morphology, prolonged circulation, biocompatibility, and broad tissue distribution.
- Poly-β-hydroxybutyrate nanoparticles improved survival and restored immune responsiveness to lipopolysaccharide rechallenge in septic mice.
- Sustained β-hydroxybutyrate release restored cellular bioenergetics through the tricarboxylic acid cycle-oxidative phosphorylation axis, with supportive ex vivo findings in septic patient monocytes.
Methodological Strengths
- Integrated nanoparticle characterization with in vitro, in vivo, and ex vivo human-cell experiments.
- Linked therapeutic effects to a specific metabolic mechanism rather than relying solely on nonspecific inflammatory markers.
Limitations
- The in vivo efficacy was demonstrated in septic mice and cannot yet establish human clinical benefit.
- The ex vivo human validation involved a small cohort, and nanoparticle dose, long-term safety, and immunological heterogeneity require further evaluation.
Future Directions: Future research should evaluate pharmacokinetics, tissue-specific exposure, toxicology, optimal treatment windows, and efficacy across biologically defined sepsis endotypes before first-in-human studies.
Sepsis-associated immunoparalysis remains a key driver of poor clinical outcomes, yet no targeted pharmacotherapies have received clinical approval. Accumulating evidence identifies cellular metabolic dysfunction as a core pathogenic driver of this state, positioning metabolic modulation as a rational therapeutic approach. Biodegradable poly-β-hydroxybutyrate nanoparticles (PHB NPs) are fabricated via emulsion-solvent evaporation to address the short in vivo half-life and systemic adverse effects of free β-hydroxybutyrate (BHB), leveraging the intrinsic integrated carrier-prodrug nature of the PHB polymer.The optimized PHB NPs formulation exhibits uniform spherical morphology, extended circulation half-life, good biocompatibility, and broad tissue biodistribution.
2. Comparative Efficacy and Safety of Corticosteroids vs. No Corticosteroids in Septic Shock Intensive Care Unit Patients: A Systematic Review and Meta-Analysis.
This PRISMA-compliant meta-analysis included 11 randomized controlled trials involving 6,332 adults with septic shock. Corticosteroids reduced 28-day mortality by 8.7% relative to control (RR 0.91, 95% CI 0.86-0.97) and shortened time to shock reversal by 1.25 days, but hyperglycemia occurred more frequently in every contributing trial.
Impact: This is the most clinically actionable synthesis in the dataset because it integrates contemporary randomized evidence and quantifies both benefit and harm. The findings support corticosteroids as a reasonable adjunct while emphasizing active glucose monitoring.
Clinical Implications: Systemic corticosteroids can be considered for adults with septic shock, particularly when shock persists despite standard resuscitation and vasopressors. Clinicians should monitor glucose closely and account for uncertainty regarding ICU length of stay and other patient-centered outcomes.
Key Findings
- Eleven randomized controlled trials with 6,332 patients and 1,929 deaths were included.
- Corticosteroids reduced 28-day mortality: pooled RR 0.91, 95% CI 0.86-0.97, P=0.008, with no observed statistical heterogeneity.
- Time to shock reversal was shortened by 1.25 days, while hyperglycemia was consistently more frequent with corticosteroids.
Methodological Strengths
- Included randomized trials and applied PRISMA 2020, Risk of Bias 2, and GRADE frameworks.
- Used restricted maximum likelihood, Hartung-Knapp-Sidik-Jonkman adjustment, prediction intervals, and publication-bias assessments.
Limitations
- The evidence base included trials with differences in corticosteroid regimens and background care.
- The analysis did not establish which patient phenotypes or dosing strategies derive the greatest benefit.
Future Directions: Future trials should compare phenotype-guided corticosteroid strategies, define optimal dose and duration, and prioritize patient-centered outcomes such as long-term functional status, infection risk, and quality of life.
BACKGROUND: Septic shock carries a high intensive care unit (ICU) mortality. The role of adjunctive corticosteroid therapy is controversial, with conflicting signals from trial-level meta-analyses, individual patient data syntheses, and large randomized trials. This review aimed to assess the comparative efficacy and safety of systemic corticosteroids versus no corticosteroids in adult ICU patients with septic shock. METHODS: Following the PRISMA 2020 guidelines, MEDLINE, Embase, CENTRAL, and Scopus were searched from inception, supplemented by trial registry and gray literature searches, for randomized trials of systemic corticosteroids versus placebo or standard care in adults with septic shock.
3. Systematic review of the current landscape and imaging-based definition of septic cardiomyopathy.
This systematic review identified 87 publications from approximately 2,669 records and found substantial heterogeneity in the definition, imaging parameters, timing, and reversibility assessment of septic cardiomyopathy. Transthoracic echocardiography was used in 70 studies, but associations between ventricular dysfunction and mortality were inconsistent, supporting the need for a unified definition and standardized longitudinal assessment.
Impact: This paper addresses a fundamental barrier to progress: septic cardiomyopathy cannot be reliably compared across studies or targeted therapeutically without a reproducible definition. Its findings provide a framework for future diagnostic studies, prognostic research, and phenotype-specific clinical trials.
Clinical Implications: Clinicians should interpret echocardiographic abnormalities in septic patients within their clinical context rather than applying a single universal threshold. Serial assessment of left- and right-ventricular systolic and diastolic function may be more informative than one early measurement.
Key Findings
- Of approximately 2,669 identified articles, 87 publications were included and only 45 provided an explicit definition of septic cardiomyopathy.
- Transthoracic echocardiography was used in 70 studies; 64% assessed cardiac function within 24 hours of admission.
- Definitions, parameters, outcomes, timing, and assessment of reversibility varied substantially, and mortality associations were inconsistent across left-ventricular, diastolic, and right-ventricular dysfunction.
Methodological Strengths
- Searched multiple major databases and synthesized a large body of imaging and outcome literature.
- Explicitly examined definitions, ventricular domains, timing, reversibility, and mortality rather than focusing on a single echocardiographic parameter.
Limitations
- Most included studies were heterogeneous observational investigations, limiting causal inference and quantitative pooling.
- The review could not determine a definitive diagnostic threshold or establish which imaging phenotype should guide treatment.
Future Directions: Consensus work should define septic cardiomyopathy using standardized biventricular systolic and diastolic parameters, incorporate serial measurements, and validate prognostic and treatment-response phenotypes in prospective multicenter cohorts.
BACKGROUND: Septic cardiomyopathy (SCM) has no current unified definition, although it can be associated with significant mortality. It encompasses a wide spectrum of cardiac dysfunction ranging from mild to severe systolic and/or diastolic dysfunction of the left and/or right ventricle. The objective of this review is to evaluate the imaging modalities and parameters used to define SCM and the clinical outcomes. METHODS: We conducted a systematic review of the literature, including studies up to August 2025, examining the impact of cardiac dysfunction, specifically related to the systolic and/or diastolic dysfunction of the left or right ventricle. We focussed on mortality and comparable phrases as the primary outcome. We considered all cardiac imaging methods.